株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創薬技術トップ10:戦略的分析と世界の予測

Top 10 Drug Discovery Technologies - Strategic Analysis and Global Forecasts

発行 MarketsandMarkets 商品コード 137811
出版日 ページ情報 英文 311 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
創薬技術トップ10:戦略的分析と世界の予測 Top 10 Drug Discovery Technologies - Strategic Analysis and Global Forecasts
出版日: 2010年11月10日 ページ情報: 英文 311 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

世界における創薬技術の主要10市場は2010年に308億米ドル近くとなり、今後CAGR11.9%で増加し2015年には540億米ドルに達すると見込まれています。

当レポートは、様々な創薬技術についての動向と機会、競合見通しをまとめ、市場に参入する企業のプロファイルも交え、概略以下の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 サマリー

第3章 市場概要

  • 市場セグメンテーション
  • ハイスループットスクリーニングとバイオ分析装置
  • 特許分析

第4章 牽引因子分析

  • 牽引因子
  • 機会

第5章 ハイスループットスクリーニング(HTS)

  • イントロダクション
  • 市場概要
  • 課題と勝利の条件
  • ウルトラハイスループットスクリーニング
  • ロボティクスとオートメーション
  • 微細化
  • ハイコンテントスクリーニング(HCS)
  • セルベース圧制

第6章 バイオ分析装置

  • イントロダクション
  • 課題と動向
  • マススペクトロメトリー
  • マイクロプレートリーダー
  • 核磁気共鳴(NMR)
  • 化学療法装置

第7章 ファーマコゲノミクス

  • イントロダクション
  • 創薬におけるファーマコゲノミクスのアプリケーション
  • 課題
  • ファーマコゲノミクス技術市場における主な動向
  • ファーマコゲノミクスの将来予測
  • ファーマコゲノミクス製品:価格効果
  • ファーマコゲノミクス技術:短期/長期的利点

第8章 コンビナトリアルケミストリー

  • イントロダクション
  • 市場因子
  • ステークホルダーの特徴
  • 課題
  • 主な動向と市場促進因子

第9章 ゲノミクス

  • イントロダクション
  • 勝利の条件
  • 機能ゲノミクス
  • 構造ゲノミクス

第10章 バイオチップ

  • イントロダクション
  • 課題
  • 業界動向
  • DNAマイクロアレイ
  • ラボオンチップ
  • プロテオミクス・マイクロアレイ

第11章 バイオインフォマティクス

  • イントロダクション
  • 課題と動向

第12章 プロテオミクス

  • イントロダクション
  • 業界動向
  • 2DGE
  • ハイブリッドシステム

第13章 RNAi

  • イントロダクション
  • 勝利の条件
  • RNAi創薬における機会
  • SiRNA
  • MiRNA
  • その他

第14章 ナノテクノロジー

  • イントロダクション
  • ナノテクノロジーの医療アプリケーション範囲
  • 課題と動向
  • 原子間力顕微鏡(AFM)
  • ナノ質量分析
  • ディップペン・ナノリソグラフィー

第15章 地域別分析

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他

第16章 競合環境

  • 創薬技術のための市場シェア
  • 提携と連携
  • 新製品上市
  • トップ10技術の最終クライアント

第17章 企業プロファイル

付録

図表

目次
Product Code: PH 1303

Abstract

Description

Top 10 drug discovery technologies - strategic analysis and global forecasts (2010 to 2015)

The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies. The applications of these technologies in the introduction of drugs for diverse diseases such as cancer, CVD, CNS disorders such as Parkinson' s and Alzheimer' s and other serious chronic diseases have created significant opportunities for the market growth in the future. The slow growth of the introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.

The global top 10 drug discovery technologies market is expected to be around $ 30.8 billion in 2010 and estimated to reach $ 54 billion mark in 2015, growing at a CAGR of 11.9 % from 2010-2015. The market for high throughput screening accounts for the largest share with approximately 33% of the entire market for top 10 drug discovery technologies. This huge market share is mainly due to the increasing applications of cell based assays and robotics in the parallel screening of compounds.

Scope of the report

This research report includes following drug discovery technologies:

  • High throughput screening (robotics and automation, cell based assays, miniaturization, high content screening and ultra high throughput screening)
  • Bioanalytical instruments (mass spectrometry, NMR, micro plate readers and chemotherapy instruments)
  • Pharmacogenomics
  • Combinatorial chemistry
  • Genomics (functional and structural genomics)
  • Biochips (DNA microarrays, lab on a chip, proteomics microarrays)
  • Bioinformatics
  • Proteomics (2DGE, two hybrid systems, isotope encoding and activity based assays)
  • RNAi (siRNA, miRNA, ddRNAi, short hairpin RNAs)
  • Nanotechnology (Atomic force microscopy, nano mass spectroscopy, dip pen nanolithography and other nanotechnologies)

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.

What makes our reports unique?

  • We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
  • We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
  • We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
  • Comprehensive market analysis for the following sectors:
    • Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

  • Which are the high-growth segments/cash cows and how is the market segmented in terms of applications and materials?
  • What are market estimates and forecasts; which markets are doing well and which are not?
  • Where are the gaps and opportunities; what is driving the market?
  • Which are the key playing fields? Which are the winning edge imperatives?
  • How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

Table of Contents

EXECUTIVE SUMMARY

  • Objective
  • Market scenario

1 INTRODUCTION

  • 1.1 Key take-aways
  • 1.2 Report description
  • 1.3 Markets covered
  • 1.4 Research methodology
  • 1.5 Stakeholders

2 SUMMARY

3 MARKET OVERVIEW

  • 3.1 Market segmentation
  • 3.2 High throughput screening & bioanalytical instruments leading the market
  • 3.3 Patent analysis

4 DRIVING FACTOR ANALYSIS

  • 4.1 Drivers
    • 4.1.1 Contract research boosting technology adoption
    • 4.1.2 Collaborations between academia & pharmaceutical industry
    • 4.1.3 Increased necessity for ADME/toxicity technologies
  • 4.2 Opportunities
    • 4.2.1 Offshoring scenario for drug discovery

5 HIGH THROUGHPUT SCREENING

  • 5.1 Introduction
  • 5.2 Market overview
  • 5.3 Burning issues & winning imperatives
    • 5.3.1 Increasing participation from academic research
    • 5.3.2 High throughput screening set up: pharmaceutical vs academic
  • 5.4 Ultra high throughput screening
  • 5.5 Robotics & automation
  • 5.6 Miniaturization
  • 5.7 High content screening
    • 5.7.1 Opportunities
      • 5.7.1.1 GPCR drug discovery
  • 5.8 Cell based assays

6 BIOANALYTICAL INSTRUMENTS

  • 6.1 Introduction
  • 6.2 Burning issues & trends
    • 6.2.1 Pharmaceutical industry a major end client
    • 6.2.2 Agilent penetration in bioanalytical instruments market
    • 6.2.3 Outsourcing scenario
  • 6.3 Mass spectrometry
    • 6.3.1 Upcoming technology - Maldi-QMS
  • 6.4 Microplate readers
  • 6.5 Nuclear magnetic resonance
  • 6.6 Chemotherapy instruments

7 Pharmacogenomics

  • 7.1 Introduction
  • 7.2 Pharmacogenomics applications in drug development
  • 7.3 Burning issues
    • 7.3.1 Commercial hurdles in drug development
      • 7.3.1.1 Cost issues in clinical development
      • 7.3.1.2 FDA approval
      • 7.3.1.3 Ethical issues
    • 7.3.2 Pharmacogenomics for drug reintroduction
    • 7.3.3 Pharmacogenomics applications in existing drugs
  • 7.4 Key trends in the pharmacogenomics technology market
    • 7.4.1 Regulatory initiatives boosting adoption for pharmacogenomics technology
    • 7.4.2 Rise in pharmacogenomics consortia boost technology based research
    • 7.4.3 Increasing importance of databases
  • 7.5 Future prospects for pharmacogenomics technology research
  • 7.6 Pharmacogenomics products: pricing effects
    • 7.6.1 Case study: high priced herceptin
    • 7.6.2 Pharmacogenomics cost effectiveness
  • 7.7 Pharmacogenomics technology: short & long term benefits
    • 7.7.1 Improvement in patient safety
    • 7.7.2 Increase in drug effectiveness
    • 7.7.3 Selection of medication for chronic diseases
    • 7.7.4 Better economic efficiency for the healthcare system
    • 7.7.5 Improved patient access to drugs

8 COMBINATORIAL CHEMISTRY

  • 8.1 Introduction
  • 8.2 Market drivers
    • 8.2.1 Technological advances boost adoption of combinatorial chemistry
    • 8.2.2 Process enhancement results in better compounds
    • 8.2.3 Collaborative approach
    • 8.2.4 Need for novel compounds acts as market opportunity
  • 8.3 Stakeholders characteristics
  • 8.4 Burning issues
  • 8.5 Key trends and market boosters
    • 8.5.1 Increased recognition of combinatorial chemistry technology
    • 8.5.2 Faster drug discovery

9 GENOMICS

  • 9.1 Introduction
  • 9.2 Winning imperatives
    • 9.2.1 Reducing cost for whole genome sequencing
  • 9.3 Functional genomics
  • 9.4 Structural genomics

10 BIOCHIPS

  • 10.1 Introduction
  • 10.2 Burning issues
    • 10.2.1 Business trends
    • 10.2.2 Patent disputes
    • 10.2.3 Competition
  • 10.3 Industry trends
    • 10.3.1 Next generation technology: microfluidics with CD-ROM
    • 10.3.2 Biochips in biomarker development
    • 10.3.3 Outsourcing the biochip technology
  • 10.4 DNA microarrays
    • 10.4.1 Market drivers
      • 10.4.1.1 Increased utilization in complex diseases
      • 10.4.1.2 Sequence data proliferation
      • 10.4.1.3 Easy-access programs
  • 10.5 Lab on a chip
    • 10.5.1. New technology & cost saving by lab on a chip boost the market
  • 10.6 Proteomics microarrays
    • 10.6.1 Burning issues and trends
      • 10.6.1.1 Technical lags
      • 10.6.1.2 Human protein microarray for multiple protein analysis

11 BIOINFORMATICS

  • 11.1 Introduction
  • 11.2 Burning issues and trends
    • 11.2.1 Outsourcing
    • 11.2.2 Allocation of grants

12 PROTEOMICS

  • 12.1 Introduction
  • 12.2 Industry trends
    • 12.2.1 Funding for proteomics research
    • 12.2.2 Proteomics in anti cancer drug discovery
  • 12.3 Two dimensional gel electrphoresis- 2DGE
  • 12.4 Two-hybrid systems

13 RNAI

  • 13.1 Technology overview
  • 13.2 Winning imperatives
    • 13.2.1 Core competency acquisition
  • 13.3 Opportunity in RNAi drug discovery
    • 13.3.1 RNAi based cholesterol drugs
    • 13.3.2 Cancer drugs
  • 13.4 SiRNA
  • 13.5 MiRNAS
  • 13.6 Other RNAi technologies

14 NANOTECHNOLOGY

  • 14.1 Introduction
  • 14.2 Healthcare application areas for nanotechnology
    • 14.2.1 Biomedical research
    • 14.2.2 Therapeutics
    • 14.2.3 Diagnostics
  • 14.3 Burning issues and trends
    • 14.3.1 Regulatory & health issues
    • 14.3.2 Increase in funding
  • 14.4 Atomic force microscopy (AFM)
  • 14.5 Nano-mass spectroscopy
  • 14.6 Dip-pen Nanolithography

15 GEOGRAPHICAL ANALYSIS

  • 15.1 Introduction
  • 15.2 North America
  • 15.3 Europe
  • 15.4 Asia
  • 15.5 ROW

16 COMPETITIVE LANDSCAPE

  • 16.1 Market share for drug discovery technologies
  • 16.2 Agreements & collaborations
  • 16.3 New product launch
  • 16.4 End clients for top 10 drug discovery technologies

17 COMPANY PROFILES

  • 17.1 ABBOTT LABORATORIES INC.
    • 17.1.1 Overview
    • 17.1.2 Primary business
    • 17.1.3 Strategy
    • 17.1.4 Developments
  • 17.2 AFFYMETRIX INC.
    • 17.2.1 Overview
    • 17.2.2 Primary business
    • 17.2.3 Strategy
    • 17.2.4 Developments
  • 17.3 AGILENT TECHNOLOGIES INC.
    • 17.3.1 Overview
    • 17.3.2 Primary business
    • 17.3.3 Strategy
    • 17.3.4 Developments
  • 17.4 ALBANY MOLECULAR RESEARCH INC.
    • 17.4.1 Overview
    • 17.4.2 Primary business
    • 17.4.3 Strategy
    • 17.4.4 Developments
  • 17.5 ARQULE INC.
    • 17.5.1 Overview
    • 17.5.2 Primary business
    • 17.5.3 Strategy
    • 17.5.4 Developments
  • 17.6 ASTRAZENECA PLC.
    • 17.6.1 Overview
    • 17.6.2 Primary business
    • 17.6.3 Strategy
    • 17.6.4 Developments
  • 17.7 BIO-RAD LABORATORIES INC.
    • 17.7.1 Overview
    • 17.7.2 Primary business
    • 17.7.3 Strategy
    • 17.7.4 Developments
  • 17.8 CALIPER LIFE SCIENCES INC.
    • 17.8.1 Overview
    • 17.8.2 Primary business
    • 17.8.3 Strategy
    • 17.8.4 Developments
  • 17.9 CELERA CORP
    • 17.9.1 Overview
    • 17.9.2 Primary business
    • 17.9.3 Strategy
    • 17.9.4 Developments
  • 17.10 CHARLES RIVER LABORATORIES INTERNATIONAL INC.
    • 17.10.1 Overview
    • 17.10.2 Primary business
    • 17.10.3 Strategy
    • 17.10.4 Developments
  • 17.11 CHEMBRIDGE CORP
    • 17.11.1 Overview
    • 17.11.2 Primary business
    • 17.11.3 Strategy
    • 17.11.4 Developments
  • 17.12 EVOTEC AG
    • 17.12.1 Overview
    • 17.12.2 Primary business
    • 17.12.3 Strategy
    • 17.12.4 Developments
  • 17.13 F. HOFFMANN-LA ROCHE LTD.
    • 17.13.1 Overview
    • 17.13.2 Primary business
    • 17.13.3 Strategy
    • 17.13.4 Developments
  • 17.14 GYROS AB
    • 17.14.1 Overview
    • 17.14.2 Primary business
    • 17.14.3 Strategy
    • 17.14.4 Developments
  • 17.15 INCYTE CORP
    • 17.15.1 Overview
    • 17.15.2 Primary business
    • 17.15.3 Strategy
    • 17.15.4 Developments
  • 17.16 LIFE TECHNOLOGIES CORP
    • 17.16.1 Overview
    • 17.16.2 Primary business
    • 17.16.3 Strategy
    • 17.16.4 Developments
  • 17.17 SHIMADZU CORP
    • 17.17.1 Overview
    • 17.17.2 Primary business
    • 17.17.3 Strategy
    • 17.17.4 Developments
  • 17.18 PERKINELMER INC.
    • 17.18.1 Overview
    • 17.18.2 Primary business
    • 17.18.3 Strategy
    • 17.18.4 Developments
  • 17.19 SIGMA-ALDRICH CORP
    • 17.19.1 Overview
    • 17.19.2 Primary business
    • 17.19.3 Strategy
    • 17.19.4 Developments
  • 17.20 TECAN GROUP LTD.
    • 17.20.1 Overview
    • 17.20.2 Primary business
    • 17.20.3 Strategy
    • 17.20.4 Developments
  • 17.21 THERMO FISHER SCIENTIFIC INC.
    • 17.21.1 Overview
    • 17.21.2 Primary business
    • 17.21.3 Strategy
    • 17.21.4 Developments

APPENDIX

  • U.S. patents
  • EUROPE patents
  • JAPAN patents

LIST OF TABLES

  • 1 Global top 10 drug discovery technologies market 2008 - 2015 ($Million)
  • 2 Estimated time saving by CRO in clinical trials
  • 3 Global high throughput screening market, by products 2008 - 2015 ($Million)
  • 4 High throughput screening market, by geography 2008 - 2015 ($Million)
  • 5 HTS infrastructural/resource comparison for pharmaceutical and academic centers
  • 6 Ultra high throughput screening market, by geography 2008 - 2015 ($Million)
  • 7 Robotics and automation market, by geography 2008 - 2015 ($Million)
  • 8 Miniaturization market, by geography 2008 - 2015 ($Million)
  • 9 High content screening market, by geography 2008 - 2015 ($Million)
  • 10 Cell based assays market, by geography 2008 - 2015 ($Million)
  • 11 Global bioanalytical instruments market, by products 2008 - 2015 ($Million)
  • 12 Bioanalytical instruments market, by geography 2008 - 2015 ($Million)
  • 13 Global mass spectrometry market, by products 2008 - 2015 ($Million)
  • 14 Mass spectrometry market, by geography 2008 - 2015 ($Million)
  • 15 Microplate Readers Market, By Geography 2008 - 2015 ($Million)
  • 16 NMR market, by geography 2008 - 2015 ($Million)
  • 17 Chemotherapy instruments market, by geography 2008 - 2015 ($Million)
  • 18 Pharmacogenomics market, by geography 2008 - 2015 ($Million)
  • 19 Combinatorial chemistry market, by geography 2008 - 2015 ($Million)
  • 20 Cost comparison between traditional and combinatorial chemistry
  • 21 Global genomics market, by products 2008 - 2015 ($Million)
  • 22 Genomics market, by geography 2008 - 2015 ($Million)
  • 23 Functional genomics market, by geography 2008 - 2015 ($Million)
  • 24 Structural genomics market, by geography 2008 - 2015 ($Million)
  • 25 Global biochips market, by segment 2008 - 2015 ($Million)
  • 26 Biochips market, by geography 2008 - 2015 ($Million)
  • 27 Patent disputes within the biochips market
  • 28 DNA microarrays market, by geography 2008 - 2015 ($Million)
  • 29 Lab on a chip market, by geography 2008 - 2015 ($Million)
  • 30 Proteomics microarrays market, by geography 2008 - 2015 ($Million)
  • 31 Global bioinformatics market, by products 2008 - 2015 ($Million)
  • 32 Bioinformatics market, by geography 2008 - 2015 ($Million)
  • 33 Global proteomics market, by products2008 - 2015 ($Million)
  • 34 Proteomics market, by geography 2008 - 2015 ($Million)
  • 35 2DGE market, by geography 2008 - 2015 ($Million)
  • 36 Two hybrid systems market, by geography 2008 - 2015 ($Million)
  • 37 Global RNAi market, by products 2008 - 2015 ($Million)
  • 38 RNAi market, by geography 2008 - 2015 ($Million)
  • 39 SiRNA market, by geography 2008 - 2015 ($Million)
  • 40 MiRNA market, by geography 2008 - 2015 ($Million)
  • 41 Global other RNAi technologies market, by products 2008 - 2015 ($Million)
  • 42 Other RNAi technologies market, by geography 2008 - 2015 ($Million)
  • 43 Global nanotechnology market, by products 2008 - 2015 ($Million)
  • 44 Nanotechnology market, by geography 2008 - 2015 ($Million)
  • 45 Comparison of AFM technology with other microscopy technology
  • 46 Atomic force microscopy market, by geography 2008 - 2015 ($Million)
  • 47 Nano-mass spectroscopy market, by geography 2008 - 2015 ($Million)
  • 48 Dip-pen Nanolithography market, by geography 2008 - 2015 ($Million)
  • 49 North American top 10 drug discovery technologies market 2008 - 2015 ($Million)
  • 50 European top 10 drug discovery technologies market 2008 - 2015 ($Million)
  • 51 Asian top 10 drug discovery technologies market 2008 - 2015 ($Million)
  • 52 RoW top 10 drug discovery technologies market 2008 - 2015 ($Million)
  • 53 Agreements and collaborations (2009 - 2010)
  • 54 New product development (2009 - 2010)

LIST OF FIGURES

  • 1 Revenue analysis for top 10 drug discovery technologies
  • 2 Top 10 drug discovery technologies market segmentation
  • 3 Relative market scenario (2010)
  • 4 Patent analysis by geography
  • 5 Patent analysis by competitors 2005 - 2010
  • 6 High throughput screening in drug discovery
  • 7 Approximate industrial demand for bioanalytical instruments (2010)
  • 8 Cost saving in comparison with high throughput screening
  • 9 Approximate end client share for microplate readers
  • 10 Drug development process and pharmacogenomics applications
  • 11 Future advancements in the pharmacogenomics research
  • 12 Cost associated with pharmacogenomics based tests
  • 13 Long term goals/benefits for pharmacogenomics
  • 14 Dollar value offered, by technology providers
  • 15 Time and cost saving by implementation of combinatorial chemistry
  • 16 Reducing costs for whole genome sequencing
  • 17 Major end clients for biochip technology market
  • 18 Historical data for DNA microarray based collaborations
  • 19 Applications of lab-on-a-chip technology in drug discovery
  • 20 MiRNA research efforts
  • 21 Applications areas of MiRNA
  • 22 MiRNA in drug discovery
  • 23 Nanotechnology applications
  • 24 Global market for top 10 drug discovery technologies
  • 25 Approximate market share for overall drug discovery technologies
  • 26 Approximate end client share for top 10 drug discovery technologies
Back to Top